Form 4: Dermata Therapeutics SVP Granted Stock Options

Dermata Therapeutics' SVP of Regulatory Affairs, Maria E Bedoya-Toro Munera, was granted 9,000 stock options with an exercise price of $2.18.

Summary

• Maria E Bedoya-Toro Munera, Senior Vice President of Regulatory Affairs at Dermata Therapeutics, Inc. (DRMA), was granted 9,000 stock options.
• The options have an exercise price of $2.18 per share.
• The grant date for these options was January 2, 2026.
• The options will vest as to 25% on the 12-month anniversary of the grant date (January 2, 2027).
• The remaining 75% will vest in 36 equal monthly installments, commencing on the 12-month anniversary of the grant date (January 2, 2027).
• The expiration date for these stock options is January 1, 2036.
• Following this transaction, Maria E Bedoya-Toro Munera beneficially owns 9,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a standard practice that aligns management incentives with shareholder interests, generally viewed as a neutral to slightly positive event for corporate governance and long-term performance.

Positives

• The grant of stock options aligns the interests of the Senior Vice President of Regulatory Affairs with those of shareholders, incentivizing long-term company performance.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction.

Industry Context

The grant of stock options to key executives is a standard practice in the biotechnology and pharmaceutical industries, aiming to attract, retain, and motivate talent by linking their compensation to the company's stock performance and long-term value creation.

Stakeholder Impact

• Shareholders: The option grant aims to align the interests of the SVP of Regulatory Affairs with shareholders, potentially leading to better long-term performance and value creation.
• Employees: This reflects standard executive compensation practices, which can influence overall employee incentive structures.

Next Steps

• The stock options will vest according to a schedule: 25% on January 2, 2027, and the remaining 75% in 36 equal monthly installments thereafter.

Key Dates

Keywords

Dermata Therapeutics, DRMA, stock option grant, executive compensation, insider transaction, Form 4, regulatory affairs